PEspeaks

May 04, 2017
Pharmaceutical Executive
Payers and pharma companies seek outcomes data for evidence-based reimbursement deals.
Apr 24, 2017
The external reference pricing circus has rolled back into town, promising another great European show. The fight-back comes via one of Europe's most obscure bodies, the European Integrated Price Information Database—better known as Euripid.
Apr 21, 2017
While technology is already impacting the pharma industry, automation and the Internet of things (IoT) will intensify over the next two years, and those companies that experiment and embrace it will have a “dramatic and competitive advantage.”
Apr 18, 2017
The Innovation Scorecard was developed to track compliance with NICE Technology Appraisals. Leela Barham reviews its latest update.
Apr 07, 2017
Curing cancer is not an impossibility anymore. Essential to any effort to achieve this will be the policies coming from President Trump’s administration, writes James Nathanielsz.
Apr 06, 2017
Pharmaceutical Executive
Two topics in Pharm Exec this month—rare disease research and women in healthcare leadership—share a "common" thread.
Apr 04, 2017
Pharmaceutical Executive
By Pharmaceutical Executive Editors
The EMA released the revised Module V- Risk Management Systems (Rev 2) of Good Pharmacovigilance Practice (GVP) (EMA/838713/2011 Rev 2) accompanied by a revised Guidance on the format of the risk management plan (RMP) in the EU.
Mar 28, 2017
Jill Wechsler outlines how the new FDA commissioner tasked with curbing regulation, speeding approvals—and collecting more fees to do it.
Mar 24, 2017
Pharmaceutical Executive
Despite the investment in place, industry still struggles to take advantage of competitive intelligence as key decision aid.
Mar 22, 2017
FDA efforts to speed more new generic drugs to market probably won’t do much to reduce high drug prices, writes Jill Wechsler.
native1_300x100
lorem ipsum